EOFlow
EOFlow is a South Korea-based medical device company that develops the EOPatch, a tubeless patch pump for automated insulin delivery, serving diabetes patients who require continuous subcutaneous insulin infusion.
- Company typePrivate
- Founded2011
- HeadquartersSeongnam, South Korea
- Headcount51–100
- GTM typeB2C
- OfferingHardware or Manufacturing
What EOFlow does
EOFlow Co. Ltd. is a South Korea-based medical device company headquartered in Seongnam that develops the EOPatch, a tubeless patch pump-based automated insulin delivery system for diabetes patients requiring continuous subcutaneous insulin infusion. The company competes directly with Insulet's Omnipod platform by offering a miniaturized, wearable form factor that eliminates the tubing of conventional insulin pumps. EOFlow operates with 51-100 employees, was founded in 2011, and trades on KOSDAQ under ticker 294090.
EOFlow's revenue model is anchored in the sale and recurring consumables of a single product line (EOPatch), targeting diabetes patients as the primary end-user persona; no distribution channels, pricing details, or named enterprise customers are publicly disclosed. The company has raised approximately $28 million across disclosed funding rounds between 2015 and 2019, led by LB Investment, and was the subject of a ~$738 million Medtronic acquisition attempt that was called off in December 2023. In parallel, EOFlow defended a multi-year trade secret dispute with Insulet in which a $452 million verdict was reduced to $60 million and ultimately overturned by the U.S. Court of Appeals for the Federal Circuit on May 29, 2026, eliminating that litigation overhang.
The commercial trajectory is constrained by single-product exposure, an absence of disclosed distribution partnerships following the collapse of the Medtronic deal, and no visible product roadmap beyond the EOPatch. Leadership comprises founder and CEO Jesse J. Kim, president Luis Malave, and chief compliance officer Ian Welsford, oriented around regulatory and compliance execution rather than scale commercialization.
EOFlow firmographics
Firmographics- Name
- EOFlow
- Legal name
- EOFlow Co. Ltd.
- Website
- https://eoflow.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- EOFlow is a South Korea-based medical device company that develops the EOPatch, a tubeless patch pump for automated insulin delivery, serving diabetes patients who require continuous subcutaneous insulin infusion.
- Ownership category
- akta.pro rank
EOFlow industry classification
Industry- Product category
- Diabetes Management Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Patch Pumps & Wearable Insulin Delivery (HLAHAHAC)
- akta.pro secondary industries
- Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF), Insulin Pumps & Patch Pumps (HLAHAIAG)
Keywords
Where EOFlow is headquartered
LocationHeadquarters
- HQ city
- Seongnam
- HQ country
- South Korea
- HQ region
- Asia
Markets served
EOFlow business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Others
EOFlow product offering
Product offeringCore offering
EOFlow develops and manufactures the EOPatch, a tubeless, wearable patch pump-based automated insulin delivery system for continuous subcutaneous insulin infusion (CSII) in diabetes management. The EOPatch is positioned as a direct competitor to Insulet's Omnipod platform in the wearable insulin delivery market, with miniaturization of the patch pump form factor as its primary technical differentiator.
Product overview
EOFlow offers a single unified product: the EOPatch, a tubeless patch pump-based automated insulin delivery system designed for people with diabetes. The EOPatch represents EOFlow's core technology focus in the wearable insulin delivery market.
Differentiator
Problem solved
Functional benefit
Brands
- EOPatch: Automated insulin delivery system using patch pump technology developed by EOFlow
Products and services
- EOPatch
Companies that use EOFlow
Customer profileSegments1 record
Ideal customer profiles1 record
EOFlow technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
EOFlow partnerships and signals
Strategic signalScale indicators3 records
Recent moves5 records
Expansion highlights3 records
EOFlow competitors and assessment
Company assessmentDirect peers
- Insulet Corporation: Insulet manufactures the Omnipod tubeless patch pump for automated insulin delivery, the closest direct competitor to EOFlow's EOPatch. Both target the same diabetes patient population seeking tubeless CSII therapy with similar form-factor and use-case propositions.
- Tandem Diabetes Care: Tandem markets the t:slim X2 insulin pump and the Tandem Mobi tubeless pump alongside AID algorithms. It is a direct peer in the automated insulin delivery category, competing for the same Type 1 diabetes patient population with comparable pump-based therapy offerings.
- Ypsomed Holding AG: Ypsomed manufactures the mylife YpsoPump and is developing its own tubeless patch pump (mylife Loop) for the AID market. It is a direct competitor in patch-pump and automated insulin delivery, particularly active in European and partner-ecosystem channels.
Broad incumbents
- Medtronic plc: Medtronic operates the MiniMed insulin pump and broader diabetes management portfolio and attempted to acquire EOFlow for ~$738M in 2023. It is a broad incumbent in diabetes devices that would integrate EOFlow's patch-pump technology into a wider portfolio including CGMs and integrated AID systems.
- Roche Diabetes Care: Roche operates the Accu-Chek insulin pump and broader diabetes care portfolio within its large diagnostics franchise. It is a broad incumbent offering insulin delivery as part of a wider diabetes management and BGM ecosystem overlapping with EOFlow's addressable market.
- Abbott Diabetes Care: Abbott manufactures the FreeStyle Libre CGM and is expanding into integrated diabetes management. As a broad incumbent with a dominant CGM franchise, it is a key ecosystem participant for AID systems including EOPatch.
- Terumo Corporation: Terumo has historically participated in insulin patch-pump development (formerly partnering with Dexcom on TypeZero) and operates a broader medical device portfolio. It is a broad incumbent with prior strategic interest in the patch-pump AID category overlapping with EOFlow's product space.
Regional players
- Sooil Development Co., Ltd. Sooil is a Korean manufacturer of the Dana Diabecare insulin pumps and a fellow South Korean competitor to EOFlow. It is a regional peer with overlapping patch/tubed pump offerings but primarily serving the domestic Korean and selected Asian markets.
Others
- Dexcom, Inc. Dexcom is the leading continuous glucose monitor (CGM) manufacturer and a key integration partner for automated insulin delivery systems. It is an ecosystem participant rather than direct competitor, but its CGM data is essential to AID systems like EOPatch.
Emerging players
- Beta Bionics: Beta Bionics developed the iLet bionic pancreas, an automated insulin dosing system competing in the AID category. As a smaller, focused entrant, it represents an emerging peer pursuing the same automated insulin delivery opportunity as EOFlow's EOPatch.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key highlights5 records
Customer concentration
EOFlow social profiles
Digital presenceEOFlow financial estimates
Financial estimateRevenue estimate
Valuation estimate
EOFlow leadership team
Management profileNumber of profiles
Profiles3 records
EOFlow funding detail
Funding detailFunding overview
Funding rounds4 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EOFlow M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EOFlow
What does EOFlow do?
EOFlow develops and manufactures the EOPatch, a tubeless, wearable patch pump-based automated insulin delivery system for continuous subcutaneous insulin infusion (CSII) in diabetes management. The EOPatch is positioned as a direct competitor to Insulet's Omnipod platform in the wearable insulin delivery market, with miniaturization of the patch pump form factor as its primary technical differentiator.
Is EOFlow a public or private company?
EOFlow is a private company. It is classified as public and is currently operating.
When was EOFlow founded?
EOFlow was founded in 2011. It employs 51 to 100 people.
Where is EOFlow based?
EOFlow is headquartered in Seongnam, South Korea, in the Asia region.
Who are EOFlow's main competitors?
Direct peers on record are Insulet Corporation, Tandem Diabetes Care and Ypsomed Holding AG. Broad incumbents are Medtronic plc, Roche Diabetes Care, Abbott Diabetes Care and Terumo Corporation. Sooil Development Co., Ltd. is listed as a regional player. Dexcom, Inc. is listed as an others. Beta Bionics is listed as an emerging player.
Does EOFlow have an API?
No public API is recorded for EOFlow.
What industry is EOFlow in?
EOFlow's product category is Diabetes Management Devices. Its primary akta.pro industry code is HLAHAHAC, Patch Pumps & Wearable Insulin Delivery, with a secondary code of HLAHAHAF, Automated Insulin Delivery (AID) / Closed-Loop Systems. Its NAICS code is 334510 and its SIC code is 3841.